Across TCGA pan-cancer cohorts, SMIM13 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SMIM13’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SMIM13 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SMIM13 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where SMIM13 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SMIM13 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.199	.008	5	view →
LSCC	All	All	−0.298	.017	4	view →
HNSC	Male	All	+0.195	.038	2	view →
LUAD	All	All	+0.244	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SMIM13 RNA expression & survival · all SMIM13 data types